The Onset of Grade ≥3 Neutropenia Is Associated With Longer Overall Survival in Metastatic Colorectal Cancer Patients Treated With Trifluridine/Tipiracil.
The aim of this report was to evaluate the onset of grade≥3 neutropenia during the first-cycle in patients with metastatic colorectal cancer (mCRC) treated with trifluridine/tipiracil and its relationship with clinical parameters of interest, such as overall survival (OS). We performed a retrospective analysis of all consecutive patients with mCRC, treated with trifluridine/tipiracil in third or later treatment lines in mCRC, at our Medical Oncology Unit between July 2017 and December 2018. We evaluated 15 patients. Median age was 63 years (range: 46-80 years). Trifluridine/tipiracil was used in third-line treatment in 10 patients (66.7%). The only serious adverse events were grade 3 (26.7%) and grade 4 (13.3%) neutropenia. Median follow-up time (FUT) was 53 months (range=17-91 months). At the last FUT, 5 patients (33.3%) were deceased. Median OS was 5 months (range=1-15 months). At the univariate analysis, the onset of grade ≥3 neutropenia at the first cycle showed a statistically positive impact on OS (p=0.046). The onset of grade ≥3 neutropenia at the first-cycle is associated with longer median OS compared to no onset of neutropenia also in real-life.